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OBJECTIVE: To determine the validity of alpha-1-acid glycoprotein as a novel biomarker for mortality in patients
with severe sepsis.
METHODS: We prospectively included patients with severe sepsis or septic shock at the emergency department
at a single tertiary referral teaching hospital. All of the patients were enrolled within the first 24 hours of
emergency department admission, and clinical data and blood samples were obtained. As the primary outcome,
we investigated the association of serum levels of alpha-1-acid glycoprotein and 96-hour mortality with logistic
regression analysis and generalized estimating equations adjusted for age, sex, shock status and Acute
Physiology and Chronic Health Evaluation II score.
RESULTS: Patients with septic shock had lower alpha-1-acid glycoprotein levels at the time of emergency
department admission compared to patients without shock (respectively, 149.1¡42.7 vs. 189.8¡68.6; p=0.005).
Similarly, non-survivors in the first 96 hours were also characterized by lower levels of alpha-1-acid glycoprotein
at the time of emergency department admission compared to survivors (respectively, 132.18¡50.2 vs.
179.8¡61.4; p=0.01). In an adjusted analysis, alpha-1-acid glycoprotein levels #120 mg/dL were significantly
associated with 96-hour mortality (odds ratio = 14.37; 95% confidence interval = 1.58 to 130.21).
CONCLUSION: Septic shock patients exhibited lower circulating alpha-1-acid glycoprotein levels than patients
without shock. Alpha-1-acid glycoprotein levels were independently associated with 96-hour mortality in
individuals with severe sepsis.
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& INTRODUCTION
The primary cause of death in septic patients is related to
organ dysfunction (1). Although the pathogenesis of multi-
ple organ dysfunction syndrome (MODS) is not completely
understood, the role of neutrophils and endothelial cells is
thought to be crucial (2,3).
In the evolution of sepsis, the initial exacerbated pro-
inflammatory response is counter-regulated through a
phenomenon known as the compensatory anti-inflamma-
tory response syndrome (CARS) (4). Acute-phase proteins
(APPs) are important components of this last phenomenon
and act by dampening the side-effects of inflammatory
reactions, promoting the adequate resolution of inflamma-
tion and restoring homeostasis (5).
Alpha-1-acid glycoprotein (AGP), also known as oroso-
mucoid, is one of the major APPs; its serum concentration
increases two- to five-fold during an acute-phase response,
such as sepsis (6). AGP is primarily synthesized by
hepatocytes, although extra-hepatic synthesis has also been
reported (6). Although the precise biological function of this
protein is not completely understood, AGP has been
reported to exhibit immunomodulatory functions in several
cells types, including leukocytes, platelets and endothelial
cells (7). In sepsis, AGP has recently been demonstrated to
be required for the maintenance of capillary permeability
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and to be partially protective in several rodent models of
shock, in which it acts to maintain the perfusion of vital
organs (8). However, AGP could potentially inhibit neu-
trophil migration to the infectious focus in experimental
models of sepsis, thus leading to inadequate bacterial
clearance and resulting in an increased death rate (9).
Because minimizing the time-to-treatment is a crucial goal
for reducing mortality, admitting septic patients to the
emergency department (ED) could reduce the variation in
the time-to-treatment that serves as a potential confounding
variable. This factor is important because the accurate
determination of the time of sepsis onset is difficult (i.e.,
there is no reliable clinical marker, such as chest pain in
acute coronary syndromes) and intensive care unit (ICU)
admission can be delayed for hours after a patient arrives in
the ED, especially in developing countries. ED-based
studies could be highly relevant for determining the
accuracy and reliability of tools used to estimate disease
severity and to predict mortality risk in septic patients (10-
12). Therefore, the aims of this study were to investigate the
serum levels of AGP in patients with severe sepsis in the ED
and to determine the utility of this glycoprotein in
predicting mortality in patients with sepsis in this setting.
& METHODS
Patients
The study protocol was reviewed and approved by our
institutional ethics committee. Informed written consent
was obtained from all enrolled patients or substitute
decision makers. This study involved a retrospective
analysis of prospectively collected data. Patients older than
18 years who were admitted to the ED of the School of
Medicine of Ribeira˜o Preto of the University of Sa˜o Paulo
(Brazil) between May 28, 2009 and October 25, 2010 and
fulfilled the diagnostic criteria for severe sepsis were
included in this study as a convenience sample within
24 hours after admission. We defined severe sepsis as sepsis
plus at least one organ dysfunction according to the
Sequential Organ Failure Assessment (SOFA) score (13).
Any value of the SOFA score ascribed for organ dysfunction
secondary to sepsis defined a patient as having severe
sepsis. Patients who met any of the following criteria or had
any of the following conditions were excluded from the
study: liver cirrhosis, hepatitis, a low neutrophil count
(,1,000 cells/mm3), a hematologic or solid malignancy,
acquired immunodeficiency disease syndrome, chronic use
of corticoids, a recent blood transfusion (within the past 10
days) and pregnancy.
To calibrate the commercial AGP kit, 16 healthy volun-
teers (each of whom provided a signed consent form) were
tested using the AGP kit as controls (mean age¡SD:
33.6¡9.6, 60% male). These assays verified that the values
generated were within the range described by the manu-
facturer.
Clinical data collection
Clinical data, including demographics and comorbidities,
and laboratory data, including the levels of C-reactive
protein (CRP), sodium, creatinine, lactate and total bilirubin;
the ratio of arterial partial pressure of oxygen to the fraction
of inspired oxygen (PaO2/FiO2); the number of white blood
cells and platelets; and all other data required to calculate
severity-of-illness scores, were prospectively collected. All
of the patients were monitored until the time of death or
hospital discharge. SOFA and Acute Physiology and
Chronic Health Evaluation II (APACHE II) (14) scores were
calculated for the first 24 hours after arrival at the ED.
Investigators who collected the clinical data were blinded to
the biological assay results. Septic shock was defined as
severe sepsis requiring the use of a vasopressor drug (a
SOFA score of 3–4).
AGP measurements
Peripheral blood was obtained from patients and col-
lected in a dry tube. All samples were stored at -70 C˚ until
further analysis. The minimum and maximum times
between storage and measurement of samples were one
month and eight months, respectively. Serum levels of AGP
were measured in our institution’s biochemistry lab using a
commercially available kit based on immunoturbidimetric
methods (Quibasa Quı´mica Ba´sica) according to the
manufacturers’ instructions.
Statistical analysis
Data were entered into a Microsoft Access database
(Microsoft, Seattle, WA), and we used Stata version 9.2
software (StataCorp, College Station, TX) for statistical
analyses. Clinical data were summarized using means¡SD
or medians with interquartile ranges (IQRs) for continuous
variables; percentages were used for categorical data. The
comparisons between groups for continuous variables were
performed using t-tests or equivalent nonparametric tests.
We used a chi-square or Fisher exact test, as appropriate, for
categorical variables. A Spearman’s rank correlation coeffi-
cient (r) was calculated to describe correlations between AGP
levels and clinical variables. Receiver-operator characteristic
(ROC) curves were constructed to evaluate the capacities of
the exposures (AGP levels, APACHE II and SOFA scores) to
predict the outcome (96-hour mortality). The area under the
curve (AUC) was obtained and employed for comparison
using a log-rank test. The primary outcome was early
mortality, which was defined as death for any reason during
the first 96 hours after ED admission. For comparison, we
defined an AGP cut-off level of .120 mg/dL, which is the
upper normal level in normal adults (i.e., 50 to 120 mg/dL as
specified by the manufacturer of our kit). An assessment of
the cutoff values for the two biomarkers of early mortality
was undertaken. The best cutoff values for the SOFA and
APACHE II score were defined as the values that maximized
the Youden index (15).
To examine the prognostic value of AGP levels at the time
of ED admission, Kaplan-Meier survival curves were
constructed stratifying AGP levels as either #120 mg/dl
or .120 mg/dl. We used multiple logistic regression for
evaluating the association of the outcome (death within
96 hours) and the exposure (AGP levels) while controlling
for possible confounders. We used forward stepwise
regression that considered demographics, clinical status
(shock) and level of organ dysfunction (APACHE II). These
variables were chosen because they were representative
and respected the conditions for multivariate analysis.
Moreover, our sample size limited the inclusion of other
variables that were not so strongly associated with the
outcome. The odds ratios and corresponding 95% con-
fidence intervals were calculated as measures of the clinical
impact of variables. All analyses were two-tailed with p-
values,0.05 denoting statistical significance.
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& RESULTS
Study population
In this study, a total of 70 patients were prospectively
included. The mortality rate within the first 96 hours after
ED admission was 15.71% (n = 11 patients). The global
mortality at 28 days was 31.43% (n = 22 patients). Baseline
clinical and laboratory parameters for survivors and non-
survivors at the 96-hour time point are summarized in
Table 1. Non-survivor patients (n = 11) exhibited higher
SOFA (p= 0.02) and APACHE II (p,0.001) scores and lower
PaO2/FiO2 ratios (p= 0.04) and were more likely to present
with septic shock (p= 0.02) than survivors (n = 59). The
primary source of infection for most patients was the
respiratory tract followed by the urinary tract (Table 1).
No significant differences in AGP serum levels were
observed between genders or based on diabetes mellitus
status. However, patients with septic shock had lower AGP
levels at ED admission when compared to patients without
shock (respectively, 149.1¡42.7 vs. 189.8¡68.6; p= 0.005).
Similarly, non-survivors in the first 96 hours were also
characterized by lower levels of AGP at ED admission
compared with survivors (respectively, 132.18¡50.2 vs.
179.8¡61.4; p= 0.01) (Table 1).
AGP levels were significantly lower in the 30 septic shock
patients (149.1¡42.7) compared to the 40 patients without
shock (189.8¡68.6; p,0.01). In addition, non-survivors
exhibited lower AGP levels both 96 hours (p = 0.018) and
28 days after ED admission (p= 0.03).
Prognostic values of AGP, APACHE II and SOFA
score
AUCs for AGP (AUC = 0.72; 95% CI = 0.56 to 0.88;
sensitivity 45.5%; specificity 88.1%; accuracy 81.4%), SOFA
(AUC = 0.72 for a value of 11; 95% CI = 0.58 to 0.87;
sensitivity 54.5%; specificity 69.5%; accuracy 67.1%) and
APACHE II (AUC = 0.81 for a value of 24; 95% CI = 0.65 to
0.97; sensitivity 81.8%; specificity 57.6%; accuracy 61.4%) are
compared in Figure 1. While we made a somewhat arbitrary
decision to use an AGP cut off of 120 mg/dl, optimization
using the Youden index allowed us to obtain the most
accurate cut-off value of 103 mg/dl (sensitivity 45.4%;
specificity 93.2%; accuracy 85.7%). All three of these
markers had a similar capacity to predict this significant
outcome, and no statistically significant differences were
observed between the markers (p.0.05).
Patients with AGP serum levels of #120 mg/dL at the
time of ED admission exhibited higher mortality within the
first 96 hours than those with higher AGP levels (.
120 mg/dl; Chi-square: 7.36; p,0.01). Figure 2 shows the
Kaplan-Meier 96-hour survival curves classified by AGP
levels at the time of admission (above or below 120 mg/dL).
The log-rank test confirmed the statistical significance of the
AGP effect (p,0.01). Logistic regression analysis indicated
that, in a model adjusted for age, gender, shock status and
APACHE II score, an AGP serum level #120 mg/dL was
still associated with increased likelihood of death within the
first 96 hours after ED admission (Table 2).
Correlation of AGP and organ dysfunction
AGP levels were inversely correlated with lactemia
(r=20.43; p= 0.0002) and SOFA scores (r=20.26;
p = 0.029). In contrast, AGP levels were directly correlated
with both CRP levels (r= 0.47; p= 0.0001) and PAO2/FiO2
ratios (r= 0.33; p= 0.006). However, while they were
statistically significant, these correlations were weak. No
significant associations with creatinine, bilirubin, age or
APACHE II scores were observed.
& DISCUSSION
For the first time, this study demonstrates that among
severe sepsis patients, low serum levels of AGP at ED
admission are associated with increased mortality at
96 hours independent of age, gender, shock status and
APACHE II score.
Death of septic patients primarily results from MODS and
refractory shock (1). The pathogenesis of organ dysfunction
is not completely understood, but several mechanisms have
Table 1 - Demographic and clinical parameters of survivors and non-survivors in the first 96 hours after emergency
department admission.
Survivors (n = 59) Non-survivors (n = 11) p-value
Male sex, n (%) 31 (52.5%) 5 (45.4%) 0.66
Age* (years) 64 (55 to 76) 68 (59 to 82) 0.22
Diabetes mellitus, n (%) 18 (30.5%) 6 (54.5%) 0.12
Site of infection
Lung, n (%) 33 (55.9%) 5 (45.5%)
Genitourinary tract, n (%) 16 (27.1%) 4 (36.3%) 0.78
Other, n (%) 10 (17.0%) 2 (18.2%)
PaO2/FiO2
" ratio, median¡SD 209¡120 131¡101 0.04
Creatinine (mg/dl), median¡SD 1.98¡1.65 2.80¡2.04 0.14
Bilirubin# (mg/dl), median¡SD 1.67¡3.03 3.73¡7.25 0.16
Lactemia1 (mg/dl), median¡SD 3.14¡1.88 5.00¡4.26 0.08
Platelet count (103/mm3), median¡SD 194¡115 189¡112 0.88
C-reactive protein¥ (mg/dl), median¡SD 19.1¡10.44 13.4¡8.84 0.13
Septic shock, n (%) 22 (37.3%) 8 (72.7%) 0.029
APACHE II score* 19 (13 to 27) 38 (24 to 41) ,0.001
SOFA score* 7 (4 to 11) 11 (8 to 14) 0.02
AGP (mg/dl), median¡SD 179.8¡61.4 132.18¡50.2 0.01
*Variable expressed as median (25th to 75th percentiles);
"n=68 patients (57 survivors611 non-survivors); #n=58 patients (50 survivors68 non-survivors); 1n=69 patients (58 survivors611 non-survivors); ¥n = 62
patients (52 survivors610 non-survivors).
APACHE, Acute Physiology and Chronic Health Evaluation; Pa02/FI02, arterial partial pressure of oxygen/fraction of inspired oxygen ratio; SD: standard
deviation; SOFA, Sequential Organ Failure Assessment score.
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been identified, including an impaired neutrophil migration
to the infectious focus combined with an inappropriate
sequestration of these cells in secondary organs, together
with endothelial dysfunction (18-20).
Several potential mechanisms could explain why AGP
levels were decreased in non-survivors: 1) the binding of
AGP to soluble or cell molecules, such as those presented on
the endothelium, could diminish its serum bioavailability; 2)
an increase in the clearance of AGP from the circulation
could result in low serum AGP levels (i.e., different
glycoforms of AGP could have different half-lives) (16);
and 3) AGP synthesis could be impaired. Given that we
excluded subjects with cirrhosis or hepatitis and because the
serum levels of CRP and bilirubin were not significantly
different between the groups, we did not favor this latter
hypothesis.
Our study indicates that, among severe sepsis patients
who arrived at the ED, those who presented with septic
shock displayed significantly lower serum AGP levels than
those without shock. Previous studies have reported
beneficial effects of AGP in models of shock (8). This
outcome may result from the high affinity of the AGP
glycan moiety to E-selectin on the surfaces of endothelial
cells, which contributes to enhanced capillary barrier
Figure 1 - Receiver operation characteristic analysis using AGP serum levels, APACHE II and SOFA as predictors of 96-hour mortality.
Figure 2 - Survival curves at 96 hours for patients grouped according to their AGP serum levels (#or.120 mg/dL).
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function and reduced leukocyte adhesion, thus maintaining
organ perfusion (17). We also identified a significant
correlation between AGP levels and other markers of organ
dysfunction; however, the correlations with these other
markers were weak and difficult to interpret.
AGP has been shown to inhibit the rolling/adhesion and
migration of leukocytes and the adhesion and aggregation
of platelets (18). These functions are also related to the direct
interaction of its glycan moiety, especially its sialyl Lewis X
(sLeX) residue, with selectins present in leukocytes and
platelets (17). Therefore, the reduction of AGP serum levels
during severe sepsis may contribute to increased leukocyte
accumulation in several organs, which is a key event leading
to organ dysfunction (19). A previous study demonstrated
that non-surviving septic patients displayed a marked
elevation of fucosylated AGP and increased expression of
SLeX groups on AGP, suggesting that these changes in AGP
glycosylation may provide prognostic value in sepsis (20).
Additionally, in agreement with our data, Seidelin et al. has
shown that the soluble levels of L-selectin (sL-selectin) are
lower in septic patients who die in the hospital than in
healthy controls or in septic patients who survive (21). It is
likely that high levels of sL-selectin can competitively
disrupt the L-selectin-mediated binding of leukocytes to
endothelial cells (21).
Aside from its beneficial role in the CARS phenomenon,
AGP can also be harmful. For example, if high levels of AGP
are present for extended periods of time, it is possible that
this can lead to immunoparalysis, which is related to
increased rates of nosocomial sepsis, MODS and death in
critically ill patients (22). Previously, in murine models of
sepsis, our group has demonstrated that administration of
AGP can inhibit the migration of neutrophils to infectious
foci, increasing the mortality of animals (9). Furthermore,
we recently demonstrated that increased AGP concentra-
tions observed during diabetes play a role in the high
susceptibility to infection in this disease (23). These results
are in apparent contradiction with our present data.
However, it should be noted that the animals involved in
both of these experimental studies did not receive anti-
biotics. As a result, even if AGP was protective against
organ dysfunction in this setting, the animals were
completely unprotected against pathogens because AGP
also impairs the recruitment of neutrophils to infectious foci,
an effect that would further jeopardize the immune
responses of the animals. In humans, the main problem in
severe sepsis is MODS, as it is possible to control bacterial
load using antibiotics. In fact, circulating AGP can represent
an important tool regulating inflammation.
Finally, the results of this study suggest that AGP
functions as a predictor of early mortality with fair to good
accuracy when measured in patients with severe sepsis at
the time of ED presentation. Although AGP is not superior
to APACHE II or SOFA scores as a predictor of early
mortality, AGP levels #120 mg/dL are the most specific
marker of this outcome.
This study has limitations. We examined a small sample
from a single institution. In addition, we were unable to
measure AGP concentrations sequentially to determine the
exact time course of the changes in serum levels of AGP.
Although the reported half-life of radiolabeled AGP is
approximately 5 days, its pharmacokinetic properties may
change in severe sepsis (24). Another potential problem
with the study could be a lack of standardized treatment,
but our institution has a protocol based on the work of
Rivers et al., and thus immediate fluid infusion and
antibiotics were similarly offered to both groups (25).
Furthermore, one caveat of the study, which is applicable
for all studies concerning sepsis, is that we cannot tell the
precise moment when the patient developed sepsis.
Nevertheless, it should be emphasized that the study was
conducted at a tertiary referral academic ED, which is
included in a referral system that prioritizes severe cases
(26).
In conclusion, AGP levels are an independent predictor of
short-term survival in patients with severe sepsis admitted
to the ED. Because AGP levels predict prognosis and
because AGP is relatively easy and inexpensive to measure,
its employment as a biomarker has the potential for
widespread utilization. A larger multi-center study should
be conducted to validate our findings.
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